Clinical Research Directory

Inclusion Criteria: * Patients must be diagnosed with a primary endometrial carcinoma. The following histologic subtypes are eligible for inclusion: endometrioid, serious, clear cell, dedifferentiated/undifferentiated, mixed epithelial, adenocarcinoma not otherwise specified, and carcinosarcoma * Initial surgical treatment must have included hysterectomy, bilateral salpingo-oophorectomy, and pelvic lymph node assessment with either sentinel lymph node mapping/sampling or pelvic lymph node dissection. Surgical assessment of the para-aortic lymph nodes is not required * Patients must have had a complete surgical resection with negative margins and no residual gross disease after surgery * Patients must have FIGO (2009) stage I-II disease (per surgical staging) * Age ≥ 18 years * Patients must be able to start radiotherapy within 12 weeks from date of surgery Exclusion Criteria: * Patients receiving chemotherapy or hormonal therapy * A prior or concurrent malignancy whose natural history or treatment would interfere with the toxicity or efficacy assessment of IVRT * Prior pelvic radiotherapy * Active genitourinary infection requiring antibiotics, except for uncomplicated urinary tract infection * History of active inflammatory bowel disease requiring treatment, including Crohn's disease and ulcerative colitis * Concurrent psychiatric or medical condition or disease which, per investigator judgement, would make them unsuitable candidates for study enrollment